Cost-Utility Analysis of Screening Intervals for Diabetic Retinopathy in Patients With Type 2 Diabetes Mellitus

Top Cited Papers
Open Access
Abstract
Diabetes mellitus is a leading cause of blindness in the United States.1 Randomized trials have clearly demonstrated that the risk of developing severe visual loss from proliferative diabetic retinopathy (PDR) and macular edema can be significantly reduced through the use of laser photocoagulation.2-5 Thus, screening, detection, and appropriate treatment of PDR and macular edema have the potential to significantly reduce the incidence of visual loss in patients with diabetes.